Aerpio pharmaceuticals, inc. (ARPO)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10
Operating activities:
Net and comprehensive loss

-23,270

-10,396

-21,400

-16,983

-17,070

-30

-28

-27

-27

-22

Adjustments to reconcile net and comprehensive loss to net cash used in operating activities:
Depreciation

76

46

51

69

57

-

-

-

-

-

Stock-based compensation

1,085

3,431

649

488

469

-

-

-

-

-

Loss on disposal of assets

-94

-

-

-

-

-

-

-

-

-

Consulting expenses related to warrants

53

-

-

-

-

-

-

-

-

-

Amortization of debt issuance costs

-

-

75

188

-

-

-

-

-

-

Interest expense related to convertible note conversion

-

-

204

2

-

-

-

-

-

-

Changes in operating assets and liabilities:
Prepaid research and development contracts

-443

441

-40

-

-

-

-

-

-

-

Other current assets

119

293

109

-

-

-

-

-

-

-

Deposits

-0

20

-

-

-

-

-

-

-

-

Accounts payable and accrued expenses

-2,217

1,864

1,604

-

-1,071

-

-

-

-

-

Accounts receivable

-

-

-

-114

60

-

-

-

-

-

Prepaid expenses and current other assets

-

-

-

-90

210

-

-

-

-

-

Accounts payable and other current liabilities

-

-

-

311

-

-

-

-

-

-

Net cash provided by financing activities

-

-

-

12,296

-

-

-

-

-

-

Decrease in prepaid expenses

-

-

-

-

-

-2

1

-1

0

0

Increase in accounts payable

-

-

-

-

-

2

-1

-1

0

1

Increase in accrued interest

-

-

-

-

-

6

5

4

3

1

Increase in accrued expenses

-

-

-

-

-

3

0

0

0

-

Increase (decrease) in accrued expenses

-

-

-

-

-

-

-

-

-

0

Net cash used in operating activities

-23,852

-5,808

-18,883

-

-17,884

-16

-23

-24

-22

-19

Net cash used in operating activities

-

-

-

-15,718

-

-

-

-

-

-

Investing activities:
Purchase of furniture and equipment

236

37

8

113

41

-

-

-

-

-

Proceeds from maturities of short-term investments

-

-

50

-

-

-

-

-

-

-

Net cash used in investing activities

-236

-37

41

-

-41

-

-

-

-

-

Financing activities:
Net cash used in investing activities

-

-

-

-113

-

-

-

-

-

-

Proceeds from exercise of stock options

-

76

36

18

3

-

-

-

-

-

Proceeds from issuances of convertible notes

-

-

297

12,542

-

-

-

-

-

-

Cash paid for debt issuance costs

-

-

-

264

-

-

-

-

-

-

Payments on notes payable, stockholders

-

-

-

-

-

-

0

0

-

-

Payments on notes payable, stockholders

-

-

-

-

-

-

-

-

0

0

Proceeds from sale of common stock

-

51,621

40,247

-

-

-

0

0

0

0

Cash paid in connection with the sale of common stock

-

3,502

3,084

-

-

-

-

-

-

-

Proceeds from notes payable, stockholders

-

-

-

-

-

15

25

25

0

35

Net cash provided by financing activities

-

48,195

37,496

-

3

15

25

25

0

35

Net decrease in cash and cash equivalents

-24,089

42,349

-

-

-

-

-

-

-

-

Net (decrease) increase in cash and cash equivalents

-

-

18,654

-3,534

-17,922

-1

1

0

-22

15

Conversion of redeemable convertible preferred stock into common stock

-

-

74,701

-

-

-

-

-

-

-

Conversion of convertible notes and accrued interest into common stock

-

-

13,447

-

-

-

-

-

-

-

Accretion of redeemable convertible preferred stock to redemption value

-

-

943

4,152

348

-

-

-

-

-

Extinguishment of redeemable convertible preferred stock

-

-

-

224

-

-

-

-

-

-